FDA approves first-in-class cancer metabolism drug
Nature Reviews Drug Discovery 16, 593 (2017).
doi:10.1038/nrd.2017.174
Author: Asher Mullard
The FDA approved Agios' and Celgene's enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells.Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The IDH enzymes normally metabolize isocitrate into α-ketoglutarate. When
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Drugs & Pharmacology | Leukemia